trending Market Intelligence /marketintelligence/en/news-insights/trending/Sqnma8R5-7f0HJznIbkU6A2 content esgSubNav
In This List

Bristol-Myers' Opdivo's new dosing regimen for skin cancer approved in EU

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022

Blog

Insight Weekly: Reviving nuclear power; 2023 outlook for US financials; PE funds fuel EV sector


Bristol-Myers' Opdivo's new dosing regimen for skin cancer approved in EU

The European Commission approved a new dosing regimen for Bristol-Myers Squibb Co.'s blockbuster drug Opdivo as an add-on treatment for certain patients with a type of skin cancer.

Opdivo's flat dosing schedule of 240 milligrams infused over 30 minutes every two weeks or 480 milligrams infused over 60 minutes every four weeks can now be used as an adjuvant treatment of adult patients with melanoma with involvement of lymph nodes or whose disease has spread to other parts and have undergone complete resection.

Melanoma is a type of skin cancer characterized by the uncontrolled growth of pigment-producing cells in the skin.

Bristol-Myers said in an Oct. 24 press release that the approval for the new dosing regimen will provide additional treatment flexibility for patients in the EU.

The drug is already approved in several countries to treat different types of cancer.